Compare BATRA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BATRA | ACAD |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | United States |
| Employees | 1610 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.8B |
| IPO Year | N/A | 2000 |
| Metric | BATRA | ACAD |
|---|---|---|
| Price | $53.53 | $21.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | ★ $60.00 | $30.55 |
| AVG Volume (30 Days) | 36.4K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $12.40 | $18.80 |
| Revenue Next Year | $8.54 | $11.70 |
| P/E Ratio | ★ N/A | $1,078.00 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $41.50 | $19.69 |
| 52 Week High | $56.06 | $28.35 |
| Indicator | BATRA | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 48.50 |
| Support Level | $52.83 | $21.12 |
| Resistance Level | $54.58 | $22.03 |
| Average True Range (ATR) | 0.90 | 0.59 |
| MACD | -0.16 | 0.05 |
| Stochastic Oscillator | 52.92 | 68.07 |
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.